Bicara raises $161.8M in public offering; reports preliminary cash of $414.8M

Bicara Therapeutics Inc.

Net proceeds of ~$161.8M from offering of 7.175M shares at $16.00/sh and 2.2M pre-funded warrants.
Preliminary unaudited cash, cash equivalents and investments as of Dec 31, 2025: ~$414.8M.
Proceeds to support commercial infrastructure for ficerafusp alfa, accelerated development, and manufacturing.
Underwriters exercised option for additional 1,406,250 shares.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Bicara Therapeutics Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives (effective 2026-02-24).

Action: entry
Agreement: underwriting
Counterparty: Morgan Stanley & Co. LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives
Effective: 2026-02-24

Exact text from the filing

On February 24, 2026, Bicara Therapeutics Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives (the “Representatives”) of the underwriters named therein (the “Underwriters”)

View on SEC.gov

Browse all material agreements →

Bicara Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-076560

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.